Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Creatine kinase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    108 result(s) found for: Creatine kinase. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2018-004882-15 Sponsor Protocol Number: EntREG-SILICOFCM Start Date*: 2019-05-21
    Sponsor Name:University Hospital Regensburg
    Full Title: Effect of angiotensin receptor neprilysin inhibitor sacubitril/valsartan on cardiopulmonary exercise tolerance in patients with hypertrophic cardiomyopathy – a randomized controlled clinical Phase ...
    Medical condition: hypertrophic cardiomyopathy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012581-32 Sponsor Protocol Number: SB-480848/033 Start Date*: 2010-01-28
    Sponsor Name:GlaxoSmithKline Research & Development, Ltd
    Full Title: A Clinical Outcomes Study of Darapladib versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE). (Short title: The Stabi...
    Medical condition: after recent Acute Coronary Syndrome (ACS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) NL (Completed) SE (Completed) DK (Completed) HU (Completed) CZ (Completed) SK (Completed) PL (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005296-81 Sponsor Protocol Number: BMN-051-303 Start Date*: 2016-05-02
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A 24 week Randomized Double-Blind, Placebo-Controlled Study followed by 72 week open-label extension to assess the efficacy, safety and tolerability of drisapersen sodium in subjects with Duchenne ...
    Medical condition: Duchenne Muscular Dystrophy (DMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005184-15 Sponsor Protocol Number: 05_ENDO_46 Start Date*: 2005-05-24
    Sponsor Name:Christie Hospital NHS Trust
    Full Title: Central Hypothyroidism and Adjusted Thyroxine dose Study (CHATS): impact of increasing free thyroxine levels in patients with hypopituitarism
    Medical condition: Central (secondary/tertiary) hypothyroidism (subclinical)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004398-76 Sponsor Protocol Number: gjnh/mccormick/01 Start Date*: 2006-03-22
    Sponsor Name:Golden Jubilee National Hospital
    Full Title: A comparison of Myocardial Protection Using Preconditioning with Sevoflurane Against High Thoracic Epidural Analgesia for CABG Surgery
    Medical condition: Ischaemic heart disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-001767-67 Sponsor Protocol Number: PTC124-GD-045-DMD Start Date*: 2020-01-30
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment with Ataluren
    Medical condition: Non-Sense Mutation Duchenne Muscular Dystrophy (nmDMD)
    Disease:
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001691-11 Sponsor Protocol Number: PTC124-GD-046-DMD Start Date*: 2020-03-06
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: Phase 2, Non-Interventional, Clinical Study to Assess Dystrophin Levels in Subjects With Nonsense Mutation Duchenne Muscular Dystrophy Who Have Been Treated With Ataluren for ≥9 Months
    Medical condition: Non-Sense Mutation Duchenne Muscular Dystrophy (nmDMD)
    Disease:
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-000238-16 Sponsor Protocol Number: APD791-202 Start Date*: 2021-05-07
    Sponsor Name:Arena Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Effect on Microvascular Obstruction of Temanogrel in Subjects Undergoing Percutane...
    Medical condition: Microvascular Obstruction
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004866 10079682 Microvascular occlusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-001277-23 Sponsor Protocol Number: ARGX-113-2007 Start Date*: 2022-10-26
    Sponsor Name:argenx BV
    Full Title: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Phar...
    Medical condition: Active Idiopathic Inflammatory Myopathy (IIM)
    Disease: Version SOC Term Classification Code Term Level
    24.1 10028395 - Musculoskeletal and connective tissue disorders 10085970 Idiopathic inflammatory myopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) BE (Trial now transitioned) LT (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) ES (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000078-65 Sponsor Protocol Number: Rituximab Start Date*: 2007-01-17
    Sponsor Name:Karolinska University Hospital
    Full Title: Rituximab in the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
    Medical condition: Adult polymyositis or adult dermatomyositis or juvenile dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10036102 Polymyositis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002376-95 Sponsor Protocol Number: RRK3535 Start Date*: 2009-01-05
    Sponsor Name:University Hospital Birmingham NHS Foundation Trust
    Full Title: Myocardial protection with Perhexiline in Left Ventricular Hypertrophy
    Medical condition: Patients with left ventricular hypertrophy undergoing aortic valve surgery (with or without coronary artery surgery)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-000980-21 Sponsor Protocol Number: PTC124-GD-048-DMD Start Date*: 2021-06-24
    Sponsor Name:PTC Therapeutics, Inc.
    Full Title: An Open-Label Study Evaluating the Safety and Pharmacokinetics of Ataluren in Children From ≥6 Months to <2 Years of Age with Nonsense Mutation Duchenne Muscular Dystrophy
    Medical condition: Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004578-16 Sponsor Protocol Number: VAL-1221-201-16 Start Date*: 2017-06-19
    Sponsor Name:Valerion Therapeutics, LLC
    Full Title: A Three-month, Open-Label, Randomized, Dose-escalation Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of VAL-1221 versus Myozyme®/Lumizyme® in Patien...
    Medical condition: Late-Onset GSD-II (Pompe Disease)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10036143 Pompe's disease LLT
    20.1 100000004850 10045253 Type II glycogen storage disease LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001497-29 Sponsor Protocol Number: RA101495-02.202 Start Date*: 2019-10-17
    Sponsor Name:Ra Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects with Immune-Mediated Necrotizing Myopathy
    Medical condition: Immune-Mediated Necrotizing Myopathy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10072156 Immune-mediated necrotizing myopathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) NL (Completed)
    Trial results: View results
    EudraCT Number: 2019-003370-35 Sponsor Protocol Number: MCT8-2019-2 Start Date*: Information not available in EudraCT
    Sponsor Name:Rare Thyroid Therapeutics International AB
    Full Title: Tiratricol treatment of children with Monocarboxylate Transporter 8 deficiency: Triac Trial II
    Medical condition: Monocarboxylate Transporter 8 (MCT8) deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Ongoing) CZ (Trial now transitioned) NL (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001710-37 Sponsor Protocol Number: NL73727 Start Date*: 2021-05-26
    Sponsor Name:Academisch Medisch Centrum
    Full Title: Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial.
    Medical condition: idiopathic inflammatory myopathies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-000657-50 Sponsor Protocol Number: PM1116197 Start Date*: 2014-05-27
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting with Acute Coronary Syndrome Treated with Losmapimod Compared to Placebo (PM1116197)...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10003723 Attack coronary LLT
    16.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    16.1 10007541 - Cardiac disorders 10071111 Non ST segment elevation acute coronary syndrome LLT
    16.1 100000004848 10041894 ST segment elevation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Prematurely Ended) IT (Completed) DE (Completed) BE (Completed) SK (Completed) DK (Completed) ES (Completed) NO (Completed) GB (Completed) CZ (Completed) HU (Completed) EE (Completed) GR (Prematurely Ended) PL (Completed) BG (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2018-004277-27 Sponsor Protocol Number: MT-1621-102 Start Date*: 2019-07-16
    Sponsor Name:Modis Therapeutics, Inc.
    Full Title: A Phase 2 open-label study of continuation treatment with combination pyrimidine nucleos(t)ides in patients with thymidine kinase 2 deficiency (TK2)
    Medical condition: Thymidine kinase 2 deficiency
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003563-22 Sponsor Protocol Number: CAT-1004-302 Start Date*: 2020-04-23
    Sponsor Name:Catabasis Pharmaceuticals Inc.
    Full Title: An Open-Label Extension Study of Edasalonexent in Pediatric Patients with Duchenne Muscular Dystrophy
    Medical condition: Duchenne Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Prematurely Ended) IE (Prematurely Ended) DE (Prematurely Ended) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004667-76 Sponsor Protocol Number: Cardoz-004 Start Date*: 2011-12-19
    Sponsor Name:Cardoz AB
    Full Title: An open-label, un-controlled, single-centre trial investigating the efficacy and safety of CRD007 tablets administered twice daily for 12 weeks in children with Duchenne Muscular Dystrophy (DMD) or...
    Medical condition: Duchenne Muscular Dystrophy (DMD), Becker Muscular Dystrophy (BMD) and symptomatic carriers for DMD or BMD
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    14.1 10010331 - Congenital, familial and genetic disorders 10059117 Becker's muscular dystrophy PT
    14.1 10010331 - Congenital, familial and genetic disorders 10052655 Duchenne muscular dystrophy gene carrier PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 09:39:10 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA